Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-long-acting human GLP-1RA for weight and gonadal function in overweight/obese adults
ChiCTR2600123091Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of supaglutide in Overweight and obesity, sponsored by Huashan Hospital. Primary endpoints: Change in fasting body weight from baseline and Change in gonadal function indexes from baseline. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
supaglutide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on ChiCTR2600123091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123091.